Compare 3M Company (MMM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Recursion Pharmaceuticals Inc — how do they compare? 3M Company trades at $160.89 (market cap $84.36B), while Recursion Pharmaceuticals Inc trades at $4.25 (market cap $2.14B). The key difference: 3M Company is far larger — about 39.4× Recursion Pharmaceuticals Inc's market cap, and 3M Company pays a 1.91% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MMM | RXRX | |
|---|---|---|
Market Cap | $84.36B | $2.14B |
Volume | 2,325,301 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $183.79 | $6.79 |
52-Week Low | $141.10 | $2.84 |
Typical Hold Time | 169 Days | 22 Days |
Enterprise Value | $93.58B | $1.66B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $161.26, down 0.53% with a bearish technical signal despite strong Q2 2026 earnings beats. The company shows robust profitability with 82.77% ROE and 11.9% net margins, though revenue has declined from 2022 peaks. Analyst consensus is mixed with 48% buy ratings and a $191 price target, while recent news highlights operational improvements and litigation management progress.
The outlook balances strong fundamentals against technical weakness and consumer segment challenges. Investment opportunity lies in continued margin expansion and industrial growth, while risks include high debt levels, soft retail demand, and ongoing PFAS litigation costs that could pressure cash flow.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
